DUBLIN--(BUSINESS WIRE)--
ICON Central Laboratories - a division of ICON plc, (NASDAQ:ICLR)
(ISIN:IE0005711209), a global provider of outsourced development
services to the pharmaceutical, biotechnology and medical device
industries - today announced results from a recent global industry
research report indicating that it ‘stands out as the service provider
that is more often than not exceeding sponsors' expectations'.
‘The State of the Central Labs Market' report, published by
Industry Standard Reports (ISR), examines the underlying dynamics of the
central laboratory services market and provides an analysis of the key
factors influencing satisfaction in central laboratories relationships
by comparing the strengths and weaknesses of the top seven global
central laboratories by market share. Its findings are based on data
generated from 105 survey respondents from 75 unique sponsor companies,
all with decision-making authority for central laboratories services.
The report found that ICON Central Laboratories currently exceeds all
competitors in three key areas: sample turnaround times, geographic
coverage and high value at low cost. According to the report, ICON
Central Laboratories ‘have focused their delivery on a core set of tests
and are providing them with a high degree of quality coupled with
excellent project management capabilities.' The report goes on to say,
‘ICON is separating itself from its peers in terms of the traditional
cost/ value matrix, [by]… meeting expectations for low cost while
performing very well and delivering high value.'
Commenting on the report, Tom O'Leary, President, ICON Central
Laboratories, said, "We're delighted with the findings of Industry
Standard Research's latest report which demonstrates that here at ICON
Central Laboratories, we continue to outperform our competitors in key
areas such as sample turnaround times, geographic coverage and high
value at low cost. We're particularly pleased with the finding that
we're the top rated central laboratory services provider for meeting
customers' quality and project management expectations. This finding
reflects quality improvement initiatives we have put in place for our
customers such as Six Sigma methodologies and MCC metrics for quality
and timeliness."
Notes to Editors:
About ICON plc:
ICON plc is a global provider of outsourced development services to the
pharmaceutical, biotechnology and medical device industries. The Company
specialises in the strategic development, management and analysis of
programs that support clinical development - from compound selection to
Phase I-IV clinical studies. ICON currently employs almost 7,800
employees, operating from 71 locations in 39 countries.
For further information, please visit www.iconplc.com
About ICON Central Laboratories
ICON Central Laboratories, a division of ICON plc, provides full
service, global central laboratory services from core facilities in the
U.S., Ireland, Singapore, India and China. An extensive test menu of
safety, esoteric and custom-developed assays, including global flow
cytometry, is complemented by dedicated, sponsor-specific project teams
and a single, comprehensive database for each study as well as a
user-friendly, web-based, secure remote data access system. ICON Central
Laboratories also offers a unique service to manage and compile
laboratory data when a client's study requires the use of local
laboratories.
For further information, please visit http://www.iconplc.com/company/service-divisions/icon-central-laboratories/
ICON/ICLR-G
ICON plc
Emily Brand
Corporate Communications Manager
+353-1-2912665
Emily.brand@iconplc.com
Source: ICON plc
News Provided by Acquire Media
